Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8968000 | 0.76 | CA12 (0.47) | CA12CA9ABCC8KCNJ11 | |
| SCHEMBL5811226 | 0.74 | CA12 (0.50) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL31487844 | 0.73 | SLC40A1 (0.38) | CA12CA9 | |
| SCHEMBL654053 | 0.73 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL16652307 | 0.73 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL7901973 | 0.70 | PARP1 (0.38) | — | |
| SCHEMBL14021242 | 0.70 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL31491273 | 0.70 | TDP2 (0.48) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL3604126 | 0.70 | TDP2 (0.48) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL6636013 | 0.70 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2CTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PNMT 3280/4885ADRA2A 571/4885ADRA2B 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.